The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $7.87 in the last session, down -4.14% from day before closing price of $8.21. In other words, the price has decreased by -$4.14 from its previous closing price. On the day, 1.05 million shares were traded. AMLX stock price reached its highest trading level at $8.21 during the session, while it also had its lowest trading level at $7.845.
Ratios:
We take a closer look at AMLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 12.05 and its Current Ratio is at 12.05. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 31 ’25 when FRATES JAMES M sold 10,896 shares for $3.47 per share. The transaction valued at 37,806 led to the insider holds 290,988 shares of the business.
Bedrosian Camille L sold 12,425 shares of AMLX for $43,082 on Mar 31 ’25. The Chief Medical Officer now owns 194,375 shares after completing the transaction at $3.47 per share. On Mar 31 ’25, another insider, Mazzariello Gina, who serves as the Chief Legal Officer of the company, sold 9,192 shares for $3.48 each. As a result, the insider received 31,954 and left with 187,969 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 701540480 and an Enterprise Value of 498854368. Its current Enterprise Value per Revenue stands at -392.181 whereas that against EBITDA is -2.412.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.46, which has changed by 3.0989585 over the last 52 weeks, in comparison to a change of 0.16260707 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $8.72, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is 32.06%, while the 200-Day Moving Average is calculated to be 69.95%.
Shares Statistics:
According to the various share statistics, AMLX traded on average about 1.46M shares per day over the past 3-months and 1700760 shares per day over the past 10 days. A total of 89.08M shares are outstanding, with a floating share count of 65.31M. Insiders hold about 26.74% of the company’s shares, while institutions hold 80.20% stake in the company. Shares short for AMLX as of 1751241600 were 6622803 with a Short Ratio of 4.55, compared to 1748563200 on 4131846. Therefore, it implies a Short% of Shares Outstanding of 6622803 and a Short% of Float of 8.189999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Amylyx Pharmaceuticals Inc (AMLX).The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.45 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.77 and -$1.98 for the fiscal current year, implying an average EPS of -$1.88. EPS for the following year is -$1.54, with 6.0 analysts recommending between -$0.95 and -$1.98.
